Investor directory

HTGF | High-Tech Gruenderfonds

High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
``` https://www.htgf.de/ ```
https://crunchbase.com/organization/high-tech-grunderfonds
https://linkedin.com/company/high-tech-grunderfonds
https://signal.nfx.com/firms/high-tech-grunderfonds
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=25144688
https://www.privateequityinternational.com/database/#/profile?id=12040

Katharina Peters

Investment Manager

Martin Pfister

Senior Investment Manager

Past deals in Health Diagnostics

Hema.to

Seed Round in 2025
Hema.to is a technology company that specializes in clinical support software designed for hematology labs. The company offers a fully automated, AI-powered solution for detecting blood cancers, utilizing flow cytometry data to generate diagnostic suggestions. By providing end-to-end decision support, Hema.to enhances the efficiency of hematology laboratories while ensuring high-quality results. Its tools are tailored specifically for the needs of clinical flow, enabling users to streamline their processes and improve diagnostic accuracy.

Avelios Medical

Series A in 2025
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.

Lindis Blood Care

Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.

Doctorflix

Seed Round in 2024
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.

Mediaire

Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.

Aignostics

Series B in 2024
Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

ABH Optics

Pre Seed Round in 2024
ABH Optics specializes in manufacturing high-quality, ultra-thin and lightweight eyeglass lenses. Their innovative lenses, designed for high myopia patients, offer enhanced comfort and aesthetic appeal without compromising vision correction. This is achieved through a proprietary material that enables significant reduction in lens thickness and weight compared to traditional lenses.

RAYDIAX

Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.

Doctorflix

Seed Round in 2023
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.

DNTOX

Seed Round in 2023
DNTOX operates a bioanalytical testing laboratory focused on animal-free screening of chemicals to assess their potential impact on brain development and developmental neurotoxicity. Utilizing an in vitro testing battery based on human cell models, the laboratory enables high-content and medium-throughput chemical screening. The process is enhanced by proprietary software that incorporates artificial intelligence, facilitating efficient analysis for the chemical, pharmaceutical, and cosmetics industries. DNTOX assists customers in identifying safe lead structures during the development of substances and supports safety assessments during the approval and re-approval processes for chemicals. The company's mission emphasizes the advancement of safe chemicals without reliance on animal testing.

Hema.to

Seed Round in 2023
Hema.to is a technology company that specializes in clinical support software designed for hematology labs. The company offers a fully automated, AI-powered solution for detecting blood cancers, utilizing flow cytometry data to generate diagnostic suggestions. By providing end-to-end decision support, Hema.to enhances the efficiency of hematology laboratories while ensuring high-quality results. Its tools are tailored specifically for the needs of clinical flow, enabling users to streamline their processes and improve diagnostic accuracy.

Nia Health

Seed Round in 2023
Nia Health GmbH is a developer of digital health applications focused on dermatological conditions such as atopic dermatitis and psoriasis. Originating from Charité Universitätsmedizin Berlin, the company creates medical software that provides personalized patient support through AI-powered apps. These solutions are designed to improve patient outcomes by offering medically validated content and tailored relief for individuals affected by chronic skin conditions. Nia Health's platform aims to reduce stigmatization and enhance the quality of life for patients with these conditions. The company's app is reimbursed by major health insurance providers in Germany, reflecting its clinical validation and effectiveness.

Mbiomics

Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.

hbox

Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.

neotiv

Seed Round in 2022
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.

Aignostics

Series A in 2022
Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

C-mo Medical Solutions

Seed Round in 2022
C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Noscendo

Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.

Ebenbuild

Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.

Lindis Blood Care

Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.

Newsenselab (M-sense)

Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Nebula Biocides

Seed Round in 2021
Nebula Biocides is a company that specializes in the development of innovative disinfection solutions aimed at effectively combating infection. The company focuses on creating application-oriented products that target persistent bacterial spores and resilient viruses, ensuring comprehensive protection for users in various environments. Nebula Biocides offers a range of smart disinfection devices designed to deliver reliable and efficient disinfection, making them suitable for diverse applications. Through its commitment to effective infection control, Nebula Biocides strives to enhance public health and safety by providing advanced disinfection technologies.

Avelios Medical

Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.

PreComb

Seed Round in 2021
PreComb is a biotechnology company focused on enhancing cancer therapy by developing innovative technologies that tailor treatments to individual patients, particularly for challenging cancers. The company specializes in automated microtumor-based profiling, which allows clinical institutions to conduct in vitro cancer diagnostics directly at the hospital. This technology enables the functional evaluation of various cancer drugs, combinations, and concentrations on patient-derived micro-tumors, thereby optimizing treatment outcomes. By improving the precision of cancer management, PreComb aims to increase success rates in therapies and ultimately enhance the quality of life for patients battling cancer.

Mediaire

Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.

heartbeat medical

Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.

Aignostics

Seed Round in 2020
Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Loewi

Seed Round in 2020
Loewi GmbH, founded in 2019 and based in Munich, Germany, operates an online platform specializing in non-pharmacy medical products, including medical self-tests and health products. As a scientific spin-off from the Technical University of Munich, the company aims to make personalized health and nutrition accessible to a wider audience. Loewi emphasizes a healthy and active lifestyle, focusing on data-driven personalization derived from evidence-based methods utilized in competitive sports over the past twelve years. The company offers personalized diet recommendations and supplements tailored to individual test results and health needs, promoting the analysis of nutrient requirements to help customers achieve their full potential. Loewi's commitment to integrating science and technology into its offerings is complemented by collaborations with leading universities and research institutions, reinforcing its role in advancing the industry.

PXL Vision

Seed Round in 2020
PXL Vision AG, established in 2017 and headquartered in Zurich, Switzerland, specializes in designing and developing advanced identity verification software solutions. Its flagship product, Daego, is a cross-platform solution that creates trusted digital identities for customer onboarding through sophisticated document and identity verification using computer vision and machine learning technologies. PXL Vision operates research and development centers in Novi Sad, Serbia, and Yerevan, Armenia, serving industries such as insurance, gambling, fintech, banking, and healthcare worldwide. The company aims to reduce customer onboarding costs, enhance conversion rates, and prevent fraud by providing unbiased, verifiable identities for secure digital interactions.

Noscendo

Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.

Lindis Blood Care

Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.

Newsenselab (M-sense)

Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

DyNAbind

Seed Round in 2019
DyNAbind GmbH is a biotech company based in Dresden, Germany, specializing in drug discovery technologies. Founded in 2015, it focuses on developing regenerable biosensor solutions and offers services in DNA-encoded chemical library synthesis, selection, and decoding. The company's proprietary Dynamic DNA-Encoded Library (D-DEL) technologies enhance the drug discovery process by providing innovative approaches to library design, selection, and validation. This results in a more efficient pathway to high-quality medicinal chemistry starting points for various protein targets. DyNAbind's platform is uniquely designed to integrate with fragment-based discovery methodologies, enabling the healthcare industry to expand its chemical space coverage effectively.

miRdetect

Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.

NAVAN Technologies

Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.

Mediaire

Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.

Plasmion

Seed Round in 2019
Plasmion GmbH is a technology company based in Augsburg, Germany, founded in 2016, specializing in plug-and-play ionization devices for various scientific and industrial applications. The company produces the SICRIT SC-20X ionization set, which includes a control unit and an ion source, along with various couplings. Plasmion's products are utilized in diverse fields such as quality control, food safety, medical diagnostics, security and forensics, emission monitoring, and laboratory research. The company aims to enhance traditional laboratory environments by providing novel sensor technology based on ambient mass spectrometry, which allows for sensitive and selective measurements. This technology not only improves laboratory capabilities but also facilitates its application in industrial process control and point-of-care diagnostics. Plasmion serves its customers through a network of sales partners in Germany and internationally.

OMEICOS Therapeutics

Series C in 2018
OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

advanceCOR

Venture Round in 2018
advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in the research, development, and commercialization of therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on personalized treatment solutions and offers a range of innovative products, including Revacept, a human Fc fusion protein designed to prevent platelet activation at sites of vascular injury. Additionally, advanceCOR develops COR-2, a recombinant protein that inhibits cholesterol uptake and foam cell generation, as well as COR-3, which targets atherosclerotic plaques and facilitates accelerated healing by binding to circulating progenitor cells. The company's portfolio also includes therapies for acute arterial thrombosis and thromboembolic diseases, such as myocardial infarction and stroke, as well as various monoclonal antibodies and fusion proteins aimed at enhancing treatment outcomes for patients with cardiovascular conditions.

Newsenselab (M-sense)

Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

neotiv

Seed Round in 2018
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.

heartbeat medical

Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.

KSK Diagnostics

Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.

Whitesonic

Seed Round in 2016
Whitesonic is a medical technology company specializing in digital dentistry solutions. It develops an ultrasound-based scanner designed for non-invasive, radiation-free dental impressions by utilizing high-frequency acoustic waves. This enables dentists to efficiently record and prepare dental data and soft tissue information. The company aims to advance its scanner prototype through further development, with plans to use it on patients as early as 2017 following successful evaluation phases.

Newsenselab (M-sense)

Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Bentekk

Seed Round in 2016
Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacturing of intelligent gas measuring systems designed for on-site analysis of contaminants. The company focuses on portable gas measurement devices that utilize gas chromatography and photo ionization detection to accurately assess volatile organic compounds and other hazardous substances. This technology is applicable across various sectors, including environmental monitoring, first response, logistics, life sciences, and the chemical industry. By providing equipment that enhances occupational health and safety, Bentekk enables better monitoring of toxic gas levels, contributing to safer working environments. As a subsidiary of Dräger Safety AG & Co. KGaA since 2017, Bentekk continues to advance its mission of improving workplace safety through innovative measurement solutions.

SeNostic Health GmbH

Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.

Abviris Deutschland

Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.

heartbeat medical

Venture Round in 2016
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.

LifeTime

Seed Round in 2016
LifeTime is a digital health application established by connected-health.eu GmbH in 2014, now operated by LifeTime GmbH since August 2019. The platform focuses on the secure digital transmission and decentralized management of medical data, facilitating efficient communication between healthcare providers and patients. LifeTime enables doctors and practice teams to digitally send medical findings, images, and other important documents, improving the accuracy and efficiency of healthcare delivery. By enhancing the understanding of health and treatment histories, LifeTime aims to streamline workflows for healthcare professionals while ensuring the secure handling of sensitive medical information.

Venneos

Seed Round in 2015
Venneos GmbH is a high-tech startup based in Stuttgart, Germany, founded in 2014 as a spin-off from the Max Planck Society. The company specializes in developing a silicon chip-based imaging system known as 'CAN-Q' for the label-free analysis of biological cells. This innovative technology, based on CAN-Spectroscopy, allows researchers to detect cellular changes that are typically invisible to other imaging technologies. Venneos' products cater to various fields, including tumor biology, immunology, and pharmacology, providing valuable insights to researchers in academia as well as professionals in the pharmaceutical and biotech industries.

Eyetronic Therapie

Venture Round in 2015
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

OMEICOS Therapeutics

Series A in 2015
OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

4 Animals AlsterScience GmbH

Venture Round in 2014
4 Animals AlsterScience GmbH is a Hamburg-based company specializing in the development of biologic drugs and feed supplements for animals. The company's innovative products are designed to enhance immune function and address various health challenges in animals, including viral diseases, tumors, inoculations, and cell therapies. By focusing on biologics, 4 Animals AlsterScience aims to provide alternatives to conventional drugs and help combat the growing issue of resistance in veterinary medicine.

Preventicus

Seed Round in 2014
Preventicus GmbH is a digital health company based in Jena, Germany, founded in 2014 by Thomas Hübner. The company specializes in developing smartphone and smartwatch applications that record and analyze vital parameters to screen for lifestyle-related health risks. Their primary offering, Preventicus Heartbeats, is a certified medical device designed to identify atrial fibrillation, aiding in stroke prevention. Utilizing technology integrated into standard smartphones and smartwatches, Preventicus provides users with access to medical-grade data that was previously only attainable through medical professionals. The company caters to a diverse clientele, including private individuals, corporate customers in occupational health management, and original equipment manufacturers (OEMs).

Predemtec

Seed Round in 2014
Predemtec GmbH is a German company established in 2011, specializing in the development and manufacture of diagnostic tests aimed at identifying risk factors for dementia and related illnesses. Based in Hennigsdorf, the company offers the Predemtec DX, a serum-based immunoassay designed for the early detection and risk assessment of senile dementia, particularly in Alzheimer's patients and those with mild cognitive impairment. This blood-based diagnostic procedure generates risk profiles by analyzing the concentration of six biomarkers using a specific algorithm, enabling healthcare providers to potentially delay the onset of dementia and mitigate its severity.

EGYM

Series B in 2014
EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. The company offers a comprehensive platform that integrates connected gym equipment and software, enabling operators to enhance the workout experience for their members. EGYM's offerings include a B2B corporate fitness subscription solution tailored for employers, as well as personalized, data-driven fitness experiences for users. This approach supports individuals in achieving their fitness goals, whether related to muscle gain, performance, or rehabilitation. EGYM's commitment to member success is reflected in its belief that the success of gym operators is intrinsically linked to the progress of their members towards improved physical and mental wellness.

microDimensions

Seed Round in 2014
microDimensions GmbH is a software development company based in Munich, Germany, specializing in solutions for the processing, analysis, and visualization of microscopic image data, particularly in the biomedical field. Founded in 2011, the company offers a range of products designed to enhance digital pathology workflows, including Voloom, an automated software for 3D reconstruction and analysis of histology specimens, and Zoom, a viewer for rapid visualization of whole slide images. Other offerings include anyslide and slidematch, which assist researchers in various histology applications such as cell counting, tumor border computation, and volume measurements. microDimensions focuses on creating efficient algorithms that meet high-quality standards and seamlessly integrate into existing customer workflows. The company also provides reconstruction and analysis services and distributes its products through partnerships.

OMEICOS Therapeutics

Seed Round in 2013
OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

Synoste

Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in innovative medical solutions for correcting skeletal deformities. The company focuses on developing a third-generation limb-lengthening system aimed at improving the conventional, often uncomfortable, procedures associated with bone-lengthening and deformation correction. By leveraging smart materials, Synoste’s technology aims to provide a less painful experience for patients while enhancing the precision and control of the treatment process. This approach not only reduces complication rates but also facilitates a quicker recovery, allowing patients to return to their normal activities sooner. Operating as a subsidiary of Globus Medical, Inc., Synoste addresses various conditions, including congenital and trauma-related limb discrepancies, as well as craniomaxillofacial deformations.

Photonics Healthcare

Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for cellular oxygen measurement. The company's flagship product, the COMET Monitor, enables healthcare professionals to assess cellular oxygen metabolism, including the availability and consumption of oxygen in tissue cells. This non-invasive device provides critical data at the bedside, allowing doctors to detect hypoxia early, evaluate tissue vitality, and make informed decisions regarding treatment interventions. By accurately measuring mitochondrial oxygen availability and tension, Photonics Healthcare aims to enhance patient care and prevent potential organ failure, thereby improving the overall effectiveness of medical interventions. Additionally, the company offers contract research programs to support further advancements in the field.

Middle Peak Medical

Series A in 2013
Middle Peak Medical is a privately held medical device company dedicated to addressing mitral valve disease through innovative technology. The company develops a proprietary device designed for both percutaneous catheter-based interventions and minimally invasive or open-heart surgical procedures. This novel device specifically targets the treatment of mitral valve regurgitation, aiming to restore proper mitral valve function in cases of both functional and degenerative conditions. By providing a new posterior surface for the anterior leaflet to seal effectively, Middle Peak Medical seeks to meet critical unmet needs in the management of mitral valve diseases.

Eyetronic Therapie

Series B in 2013
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

Rodos BioTarget

Venture Round in 2013
Rodos BioTarget GmbH, established in 2008 and headquartered in Hanover, Germany, is a biopharmaceutical company specializing in the development of targeted drug delivery systems using nanotechnology. The company's flagship product, TargoSphere®, is a patented nanocarrier platform designed to selectively deliver therapeutic agents directly into antigen-presenting cells. This technology has shown promise in various infectious disease models caused by viruses such as HCV and HIV, and bacteria like MRSA. Rodos BioTarget aims to expand its applications to other disorders involving immune response dysregulation, including chronic inflammations, cancers, allergies, and autoimmune diseases.

AYOXXA

Series A in 2012
AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.

Epivios

Venture Round in 2012
Epivios GmbH is a molecular diagnostics company based in Düsseldorf, Germany, specializing in the early detection of bladder and prostate cancer. Founded in 2011 as a spin-off from Heinrich Heine University, Epivios employs an interdisciplinary team of doctors and biologists who have been developing innovative epigenetic procedures for cancer diagnosis since 2009. The company's proprietary epigenetic platform technology incorporates a unique standardization tool that facilitates the comparison of samples with varying genetic backgrounds. This advancement allows for a comprehensive analysis of genetic sequences across the entire genome, enhancing the accuracy and effectiveness of cancer diagnostics.

Eyesight & Vision GmbH

Seed Round in 2011
Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive error measurement during cataract surgery. The company's flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enhances surgical precision by providing surgeons with real-time data on the refractive power of the eye and the positioning of intraocular lenses (IOLs). This innovative system employs patented "flying spot" technology, facilitating rapid and reliable measurements that integrate seamlessly with existing surgical microscopes. Eyesight & Vision GmbH focuses on optimizing the selection and placement of IOLs, ultimately aiming to improve patient outcomes and satisfaction in refractive cataract and lens surgeries.

Humedics

Series A in 2011
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in developing innovative solutions for liver function assessment. The company's flagship product, the LiMAx test, is a breath analysis device that enables real-time measurement of liver function in patients with liver failure. This easy-to-use bedside system includes a medical device, breath masks, and a diagnostic drug, allowing clinicians to accurately quantify liver function capacity. The LiMAx test is utilized in various clinical applications, such as evaluating liver function prior to and following liver transplantation, planning for living donor liver resection, and assessing conditions like liver cirrhosis. With its technology already benefiting thousands of patients, Humedics is actively expanding its global operations to enhance patient outcomes through tailored medical treatment.

Capical

Seed Round in 2011
Capical GmbH is a German company specializing in the development and marketing of innovative electrocardiography (ECG) devices that utilize capacitive electrode technology for contact-free patient monitoring. Founded in 2010 and based in Braunschweig, Capical has established itself as a leader in this field, focusing on high-resolution ECG measurements that allow healthcare professionals to assess heart activity without direct skin contact. The company’s technology finds applications beyond healthcare, including in automotive and furniture sectors, where it can monitor driver states and physiological parameters in various settings. Capical is committed to research and development, continuously enhancing its product offerings, and has received multiple awards for its achievements in technology transfer and innovation. The company aims to enhance the quality of life for individuals, especially the elderly or those with health challenges, while also improving safety and comfort in automated driving environments.

Lophius Biosciences

Venture Round in 2011
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.

EGYM

Pre Seed Round in 2011
EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. The company offers a comprehensive platform that integrates connected gym equipment and software, enabling operators to enhance the workout experience for their members. EGYM's offerings include a B2B corporate fitness subscription solution tailored for employers, as well as personalized, data-driven fitness experiences for users. This approach supports individuals in achieving their fitness goals, whether related to muscle gain, performance, or rehabilitation. EGYM's commitment to member success is reflected in its belief that the success of gym operators is intrinsically linked to the progress of their members towards improved physical and mental wellness.

Gilupi

Series C in 2011
GILUPI GmbH is a medical device company based in Potsdam, Germany, specializing in the development and production of diagnostic products aimed at the in vivo isolation of rare cells from circulating blood. The company's primary focus is on isolating tumor cells, utilizing devices that employ predetermined selectivity of antibodies bound to nano-detectors. This technology enables healthcare professionals to effectively isolate circulating tumor cells within patients' blood, facilitating more precise diagnoses and tailored therapeutic interventions. GILUPI's devices are CE certified, ensuring their compliance with safety and efficacy standards, which enhances their credibility and utility in clinical settings.

ChromoTek

Venture Round in 2010
ChromoTek GmbH is a biotechnology company based in Planegg-Martinsried, Germany, founded in 2008. The company specializes in the development of innovative immunologic research tools and detection reagents aimed at enhancing proteomics and cell biology applications. ChromoTek's products are derived from single domain camel antibodies, providing advanced solutions for health institutions and researchers. By offering these unique tools, ChromoTek aims to improve research capabilities and outcomes in various scientific fields worldwide.

Lophius Biosciences

Series B in 2010
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.

Delphi Optics GmbH

Seed Round in 2010
Delphi Optics GmbH is a Germany-based company that develops and distributes automatic, optical classification systems for medical applications. It was founded in 2009 and is headquartered in Lübeck, Schleswig-Holstein.

Humedics

Seed Round in 2010
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in developing innovative solutions for liver function assessment. The company's flagship product, the LiMAx test, is a breath analysis device that enables real-time measurement of liver function in patients with liver failure. This easy-to-use bedside system includes a medical device, breath masks, and a diagnostic drug, allowing clinicians to accurately quantify liver function capacity. The LiMAx test is utilized in various clinical applications, such as evaluating liver function prior to and following liver transplantation, planning for living donor liver resection, and assessing conditions like liver cirrhosis. With its technology already benefiting thousands of patients, Humedics is actively expanding its global operations to enhance patient outcomes through tailored medical treatment.

Eyetronic Therapie

Series B in 2010
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

Rodos BioTarget

Seed Round in 2009
Rodos BioTarget GmbH, established in 2008 and headquartered in Hanover, Germany, is a biopharmaceutical company specializing in the development of targeted drug delivery systems using nanotechnology. The company's flagship product, TargoSphere®, is a patented nanocarrier platform designed to selectively deliver therapeutic agents directly into antigen-presenting cells. This technology has shown promise in various infectious disease models caused by viruses such as HCV and HIV, and bacteria like MRSA. Rodos BioTarget aims to expand its applications to other disorders involving immune response dysregulation, including chronic inflammations, cancers, allergies, and autoimmune diseases.

PluriSelect

Venture Round in 2009
PluriSelect is a developer of biotechnical devices and supplies that focus on providing efficient tools for cell and protein separation. The company's products facilitate the isolation of cells from various sources, including whole blood, buffy coat, and cell culture, as well as other heterogeneous biological liquids. By enabling researchers to isolate specific targets from unbound materials, PluriSelect's solutions help academic scientists achieve high-quality results while minimizing the time and resources required for routine tasks.

Eyetronic Therapie

Seed Round in 2009
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

Public Health Solutions

Venture Round in 2008
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Lophius Biosciences

Seed Round in 2008
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.

HAPILA

Seed Round in 2008
HAPILA GmbH, founded in 2007 and based in Gera, Germany, specializes in pharmaceutical and chemical development services. The company focuses on the purification and processing of active pharmaceutical ingredients, providing solutions that encompass process development, analytical method development, and regulatory affairs consultancy. HAPILA’s services include quality control of raw materials, drug substances, and intermediates; cleaning validation; and the certification of reference standard substances. It also engages in the research, development, and manufacture of sophisticated active pharmaceutical ingredients, catering primarily to the pharmaceutical and biotech sectors. The company prides itself on flexibility and ethical business practices, fostering trust and cooperation with clients through open communication. As an independent enterprise, HAPILA is committed to continuous growth in its personnel and technological capabilities to enhance its development and manufacturing capacities.

Sense Inside

Venture Round in 2008
Sense Inside is a company that specializes in the development of a unique diagnostic and therapeutic device aimed at addressing bruxism, a condition characterized by pathological teeth grinding. The device is designed to provide long-term solutions for both diagnosis and treatment, catering to a growing patient population experiencing significant physiological strain associated with dental issues. By enabling healthcare professionals to effectively diagnose and manage bruxism, Sense Inside plays a crucial role in the broader context of dental health and patient care.

awenydd diagnostics GmbH

Venture Round in 2008
awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.

Public Health Solutions

Series A in 2006
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Scylab medic

Series A in 2006
Scylab medic develops an environment sensing device for blind and visually impaired people. Its products include feelix, a light device that uses a 3D sensor to facilitate the user to partially recognize surroundings without physically touching, as well as to identify stationary and moving objects. The company was founded in 2006 and is based in Leipzig, Germany.

multiBIND biotec

Venture Round in 2006
multiBIND biotec GmbH, founded in 2005 and based in Dortmund, Germany, specializes in the development of innovative solutions for decontamination and disinfection. The company's flagship technology, bioDECONT®, effectively addresses issues related to horizontal gene transfer by facilitating the removal of genetic material, proteins, and lipids. Additionally, multiBIND biotec offers bioCLEAN, which provides antimicrobial and antiviral solutions, and CleanExtract, a rapid assessment tool for microbial ATP levels in various challenging substances, including lubricants and emulsions. Through its focus on molecular genetics and biomedicine, multiBIND biotec aims to enhance safety and efficacy in environments requiring stringent contamination control.

awenydd diagnostics GmbH

Seed Round in 2006
awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.